• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Astrotech Reports Third Quarter of Fiscal Year 2025 Financial Results

    5/13/25 4:30:00 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ASTC alert in real time by email

    AUSTIN, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the third quarter of fiscal year 2025, which ended March 31, 2025.

    Thomas B. Pickens, III, Astrotech's Chairman, Chief Executive Officer and Chief Technology Officer, said, "Our customizable, portable and field updatable mass spectrometry instruments have the potential to be a game changer in a growing list of large end markets such as airport security and cargo scanning, narcotics detection, environmental monitoring and chemical processing. I am very proud of our team's accomplishments, as we now have launched four product lines that we believe will expand our sales opportunities to potential customers from around the world. We have been serving airports worldwide with 1st Detect's explosive trace detection products in 15 countries having earned a valuable track record for delivering and maintaining our instruments."

    Pickens continued, "Our Pro-Control product line now includes in-situ process controls for automatic chemical manufacturing optimization. Decisions are progressing and many quotes are pending, and we are very encouraged with the testing we have completed with some of the largest chemical and petrochemical companies. We are currently focused on selling and marketing all our brands. With our newest product lines, the TRACER NTD, Pro-Control, and EN-SCAN we believe we have created great momentum in fiscal year 2025 and into fiscal year 2026 and are very excited about our future."

    Financial Highlights & Recent Developments

    • Fiscal year 2025 Q3 revenue of $534 thousand, compared to $50 thousand in fiscal year 2024 Q3, is comprised of TRACER 1000™ shipments, a government grant, and recurring consumable sales and maintenance services.
    • On January 14, 2025, our 1st Detect subsidiary announced that it was awarded research and development contract 70RSAT24CB0000015 with the Department of Homeland Security ("DHS") to research, develop and mature the TRACER 1000 for DHS next generation explosives trace detection.
    • On January 23, 2025, we announced that 1st Detect received a $429 thousand purchase order for its TRACER 1000™ ETDs from Intuitive Research and Technology Corporation, a TSA contractor, which was fulfilled and recognized as revenue during the three months ended March 31, 2025.
    • On February 28, 2025, the Company announced that it had created a new wholly owned subsidiary, EN-SCAN, Inc., to manufacture and sell a new line of instruments built for environmental testing applications using its proprietary ATi Gas Chromatograph and Astrotech Mass Spectrometer Technology™.
    • On March 10, 2025, we announced the TRACER 1000 NTD has been configured to screen for a range of synthetic opiates and novel psychoactive substances delivering accuracy and speed to counter the global drug crisis.
    • Astrotech's consolidated balance sheet remains strong with $20.9 million in cash, cash equivalents and liquid investments to support the Company's completion of R&D projects and transition into a selling and marketing focused company. Cash, cash equivalents and liquid investments were $31.9 million at June 30, 2024.

    About Astrotech Corporation

    Astrotech (NASDAQ:ASTC) is a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology through its wholly owned subsidiaries. 1st Detect develops, manufactures, and sells trace detectors for use in the security and narcotics detection market. AgLAB develops and sells process analyzers for use in the agriculture market. Pro-Control produces products for the in-situcontrol of the chemical manufacturing processes. BreathTech is developing a breath analysis tool to screen for volatile organic compounds that could indicate infections or critical conditions. EN-SCAN, Inc. develops advanced environmental testing and monitoring solutions, integrating gas chromatography and mass spectrometry technology in rugged, portable designs for rugged environments. Astrotech is headquartered in Austin, Texas. For information, please visit www.astrotechcorp.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east and the COVID-19 pandemic, the Company's use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company's Securities and Exchange Commission filings including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    Company Contact: Ryan Polk, Chief Financial Officer, Astrotech Corporation, (512) 737-7378.

    Investor Contact: Matt Kreps, Managing Director, Darrow Associates, (214) 597-8200, [email protected].

    Financial tables follow

    ASTROTECH CORPORATION AND SUBSIDIARIES
    Condensed Consolidated Statements of Operations and Comprehensive Loss
    (In thousands, except per share data)
    (Unaudited)
     
      Three Months Ended  Nine Months Ended 
      March 31,  March 31, 
      2025  2024  2025  2024 
    Revenue $534  $50  $829  $1,590 
    Cost of revenue  297   42   428   867 
    Gross profit  237   8   401   723 
    Operating expenses:                
    Selling, general and administrative  2,115   1,833   5,842   5,501 
    Research and development  1,989   1,708   6,375   5,158 
    Total operating expenses  4,104   3,541   12,217   10,659 
    Loss from operations  (3,867)  (3,533)  (11,816)  (9,936)
    Other income and expense, net  234   379   896   1,229 
    Net loss $(3,633) $(3,154) $(10,920) $(8,707)
    Weighted average common shares outstanding:                
    Basic and diluted  1,665   1,633   1,663   1,632 
    Basic and diluted net loss per common share:                
    Net loss per common share $(2.18) $(1.93) $(6.57) $(5.34)
    Other comprehensive loss, net of tax:                
    Net loss $(3,633) $(3,154) $(10,920) $(8,707)
    Available-for-sale securities:                
    Net unrealized gain  139   13   236   284 
    Total comprehensive loss $(3,494) $(3,141) $(10,684) $(8,423)
     



    ASTROTECH CORPORATION AND SUBSIDIARIES
    Condensed Consolidated Balance Sheets
    (In thousands, except share and per share data)
     
      March 31,  June 30, 
      2025  2024 
      (Unaudited)    
    Assets        
    Current assets        
    Cash and cash equivalents $2,812  $10,442 
    Short-term investments  18,057   21,474 
    Accounts receivable  516   77 
    Contract Asset  7   — 
    Inventory, net:        
    Raw materials  2,296   2,038 
    Work-in-process  146   66 
    Finished goods  310   370 
    Prepaid expenses and other current assets  431   261 
    Total current assets  24,575   34,728 
    Property and equipment, net  2,486   2,763 
    Intangible asset, net  50   — 
    Operating lease right-of-use assets, net  35   119 
    Other assets, net  346   30 
    Total assets $27,492  $37,640 
    Liabilities and stockholders' equity        
    Current liabilities        
    Accounts payable $616  $373 
    Payroll related accruals  928   1,174 
    Accrued expenses and other liabilities  882   754 
    Lease liabilities, current  66   227 
    Total current liabilities  2,492   2,528 
    Accrued expenses and other liabilities, net of current portion  193   232 
    Lease liabilities, net of current portion  55   73 
    Total liabilities  2,740   2,833 
    Commitments and contingencies (Note 14)        
    Stockholders' equity        
    Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at March 31, 2025, and June 30, 2024  —   — 
    Common stock, $0.001 par value, 250,000,000 shares authorized at March 31, 2025, and June 30, 2024, respectively; 1,704,269 and 1,712,045 shares issued at March 31, 2025, and June 30, 2024, respectively; 1,693,953 and 1,701,729 outstanding at March 31, 2025, and June 30, 2024, respectively  190,643   190,643 
    Treasury shares, 10,316 at March 31, 2025, and June 30, 2024, respectively  (119)  (119)
    Additional paid-in capital  83,109   82,480 
    Accumulated deficit  (247,940)  (237,020)
    Accumulated other comprehensive loss  (941)  (1,177)
    Total stockholders' equity  24,752   34,807 
    Total liabilities and stockholders' equity $27,492  $37,640 
     


    Primary Logo

    Get the next $ASTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ASTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Astrotech Reports Third Quarter of Fiscal Year 2025 Financial Results

      AUSTIN, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the third quarter of fiscal year 2025, which ended March 31, 2025. Thomas B. Pickens, III, Astrotech's Chairman, Chief Executive Officer and Chief Technology Officer, said, "Our customizable, portable and field updatable mass spectrometry instruments have the potential to be a game changer in a growing list of large end markets such as airport security and cargo scanning, narcotics detection, environmental monitoring and chemical processing. I am very proud of our team's accomplishments, as we now have launched four product lines that we bel

      5/13/25 4:30:00 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 1st Detect Unveils Enhanced TRACER 1000 Narcotics Trace Detector Intended to Combat Synthetic Opiates and Novel Psychoactive Substances

      AUSTIN, Texas, March 10, 2025 (GLOBE NEWSWIRE) --  Astrotech Corporation (NASDAQ:ASTC) today announced the launch of its enhanced TRACER 1000™ Narcotics Trace Detector ("TRACER 1000 NTD") from its 1st Detect subsidiary. This innovative mobilized mass spectrometer is specifically configured to screen for the full range of synthetic opiates and novel psychoactive substances ("NPS"), delivering accuracy and speed to counter the global drug crisis. Improving Drug Detection with Advanced Mass Spectrometry The latest iteration of the TRACER 1000 NTD represents a significant leap forward in portable trace detection. Unlike conventional methods, the TRACER 1000 NTD leverages cutting-edge mass sp

      3/10/25 8:30:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Creates New Subsidiary EN-SCAN, Inc.

      AUSTIN, Texas, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) announced today that it has created a new wholly owned subsidiary, EN-SCAN, Inc. ("EN-SCAN"), to manufacture and sell a new line of instruments built for environmental testing applications using its proprietary ATi Gas Chromatograph ("GC") and Astrotech Mass Spectrometer Technology™ ("MS"). The EN-SCAN product line has been designed for outdoor field work that can be used on-site for real-time air, water, and soil analysis providing instant feedback for accurate contamination source location and migration. "EN-SCAN has been developed to fill a gap in the environmental testing market needing a durable and

      2/28/25 8:30:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Astrotech Corporation (DE)

      10-Q - ASTROTECH Corp (0001001907) (Filer)

      5/14/25 9:20:19 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Corporation (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ASTROTECH Corp (0001001907) (Filer)

      5/13/25 4:33:56 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Corporation (DE) filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ASTROTECH Corp (0001001907) (Filer)

      3/10/25 8:31:49 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Polk Ryan claimed no ownership of stock in the company (SEC Form 3)

      3 - ASTROTECH Corp (0001001907) (Issuer)

      1/24/25 7:05:31 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • New insider Stober Eric claimed ownership of 7,331 shares (SEC Form 3)

      3 - ASTROTECH Corp (0001001907) (Issuer)

      12/23/24 8:59:46 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • New insider Winn Charles Arch claimed ownership of 12,603 shares (SEC Form 3)

      3 - ASTROTECH Corp (0001001907) (Issuer)

      12/23/24 8:59:29 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    Financials

    Live finance-specific insights

    See more
    • Astrotech Announces Listing to the GSA as an Approved United States Government Vendor

      Astrotech Announces Listing to the GSA as an Approved United States Government Vendor AUSTIN, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation (1st Detect), announce that 1st Detect's TRACER 1000TM is now listed in the U.S. General Services Administration (GSA) IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290.   IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world. GSA's thoro

      4/8/24 9:00:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech to Showcase the Tracer 1000 Trace Detector at ISC West Conference

      AUSTIN, Texas, April 02, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it will be showcasing its TRACER 1000 Narcotics Trace Detector ("NTD") and Explosives Trace Detector ("ETD") at the International Security Conference and Exposition, also known as ISC West, in Las Vegas, Nevada, from April 9-12, 2024, in booth number 2067. The TRACER 1000 is a high-performance laboratory instrument that is powered by the Astrotech Mass Spectrometer Technology™ ("AMS Technology"). Our mass spectrometer is capable of rapid detection of trace levels of narcotic or explosive compounds in

      4/2/24 9:00:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Introduces the "Gold Standard" of Mass Spectrometry into Narcotics Detection Market with its State-of-the-Art Tracer 1000

       AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (NTD). The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds. Currently, the Company's Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world. The NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo,

      3/25/24 9:00:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Astrotech Corporation (DE)

      SC 13D - ASTROTECH Corp (0001001907) (Subject)

      6/26/23 4:00:53 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Astrotech Corporation (DE) (Amendment)

      SC 13G/A - ASTROTECH Corp (0001001907) (Subject)

      2/8/23 5:29:16 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Astrotech Corporation (DE) (Amendment)

      SC 13G/A - ASTROTECH Corp (0001001907) (Subject)

      2/8/23 4:02:50 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $ASTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Jaime Hinojosa Resigns as Chief Financial Officer to Work in Family Business

      AUSTIN, Texas, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") announced the resignation of its Chief Financial Officer, Jaime Hinojosa, effective February 14, 2025.   Mr. Hinojosa will continue to serve in the CFO role until February 14, 2025, and after that time will provide transition services to the Company on a consulting basis through June 30, 2025. In connection with this development, the Company and its Board of Directors have appointed Ryan Polk to serve as interim Chief Financial Officer. "I will be moving to Houston to be closer to family and to work for our family business," said Mr. Hinojosa. "I am grateful to Tom Pickens,

      1/24/25 8:30:00 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Astrotech Reports First Quarter of Fiscal Year 2024 Financial Results

      AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the first quarter of fiscal year 2024, which ended September 30, 2023. Financial Highlights & Recent Developments  Astrotech's consolidated balance sheet remains strong with $39 million in cash and liquid investments, which are anticipated to support our research and development, organic growth, and potential acquisition targets.Revenue for the quarter totaled $425 thousand compared to $38 thousand in the first quarter of the prior year due primarily to ongoing fulfillment of the previously announced 17-unit order for the TRACER 1000™ expl

      11/13/23 4:30:30 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • LogicMark Expands its Board of Directors by Naming Carine Schneider and Tom Wilkinson as Company's Innovative Product Pipeline Continues to Grow (Updated with Additional Details)

      LOUISVILLE, Ky., Oct. 31, 2023 (GLOBE NEWSWIRE) -- LogicMark, Inc. (NASDAQ:LGMK) (the "Company"), creator of the most innovative personal safety and security technology designed for the care economy, today announced that Carine Schneider, FGE, and Tom Wilkinson will join as the newest members of its Board of Directors. Ms. Schneider and Mr. Wilkinson both bring decades of corporate governance, finance, operations, technology, M&A, advisory and CEO experience. "I am thrilled to welcome Carine and Tom to our Board of Directors. Carine's demonstrated history of leadership and innovation in the technology and finance sectors, coupled with Tom's extensive experience and influential work with a

      10/31/23 11:54:15 AM ET
      $ASTC
      $LGMK
      $SONM
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Specialties
      Health Care

    $ASTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Becker James Frank bought $19,675 worth of shares (2,034 units at $9.67), increasing direct ownership by 14% to 16,121 units (SEC Form 4)

      4 - ASTROTECH Corp (0001001907) (Issuer)

      5/30/24 9:16:58 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Hinojosa Jaime bought $8,541 worth of shares (900 units at $9.49), increasing direct ownership by 13% to 7,881 units (SEC Form 4)

      4 - ASTROTECH Corp (0001001907) (Issuer)

      5/28/24 9:46:54 AM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wilkinson Thomas Wiley bought $10,536 worth of shares (1,109 units at $9.50), increasing direct ownership by 6% to 20,862 units (SEC Form 4)

      4 - ASTROTECH Corp (0001001907) (Issuer)

      5/21/24 12:54:36 PM ET
      $ASTC
      Biotechnology: Laboratory Analytical Instruments
      Industrials